Please check your internet connection and try again.
# Clobazam Oral Formulation
## Overview
A 1,5-substituted benzodiazepine with potent anticonvulsant properties. Undergoes extensive hepatic metabolism via CYP3A4/3A7 to N-desmethylclobazam, an active metabolite with a prolonged half-life (~7 days). Carries a Boxed Warning for profound sedation, respiratory depression, coma, or death when combined with opioids. Risk of tolerance, physiological dependence, and withdrawal seizures necessitates cautious initiation and structured tapering.
## Primary Indications
- **FDA-Approved:** Adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS) in patients ≥2 years of age.
- **Off-Label:** Refractory focal/generalized epilepsy, treatment-resistant anxiety, catamenial epilepsy, and short-term insomnia management. (Off-label use requires documented risk-benefit assessment and informed consent.)
## Adult Dosing
- **Initial:** 5 mg once daily at bedtime.
- **Titration:** Increase by 5–10 mg/day at intervals of 2–4 weeks based on tolerability and clinical response.
- **Maximum:** 40 mg/day, typically divided into two doses. Doses >40 mg/day rarely provide additional benefit but significantly increase adverse effects.
- **Administration:** Tablets or oral suspension. Administer consistently relative to meals.
## Pediatric Dosing
- **Eligibility:** ≥2 years. Safety/efficacy <2 years not established.
- **Initial (weight-based):**
- <30 kg: 2.5 mg once daily
- ≥30 kg: 5 mg once daily
- **Titration:** Increase by 2.5–5 mg/day (≈0.1–0.3 mg/kg/day) every 2–4 weeks.
- **Maximum:**
- <30 kg: 20 mg/day
- ≥30 kg: 30 mg/day
- *Note: Exact titration schedules and ceiling doses may vary by regional guideline or institutional protocol; verify before prescribing.*
## Dose Adjustments
- **Strong CYP3A4 Inhibitors (e.g., fluconazole, ketoconazole, verapamil, clarithromycin, grapefruit):** Reduce initial clobazam dose by 50% and cap maximum dose at 50% of standard. Re-evaluate within 2 weeks.
- **Strong CYP3A4 Inducers (e.g., carbamazepine, phenytoin, phenobarbital, rifampin, St. John’s wort):** Expect reduced parent/metabolite levels. May require upward dose titration; monitor seizure frequency and sedation.
- **Hepatic Impairment:** Start at lowest recommended dose; titrate slowly. Avoid in severe impairment unless benefits clearly outweigh risks.
- **Renal Impairment:** No formal adjustment required, but monitor for delayed metabolite clearance and excessive CNS depression.
- **Geriatric:** Initiate ≤5 mg/day; target maintenance ≤20 mg/day. Higher susceptibility to falls, cognitive impairment, and respiratory depression.
## Contraindications
- Known hypersensitivity to clobazam or other benzodiazepines.
- Acute narrow-angle glaucoma.
- Severe respiratory insufficiency, obstructive sleep apnea, or severe hepatic dysfunction.
- Concurrent opioid prescription unless alternative analgesics are inadequate and intensive monitoring is guaranteed (Boxed Warning scenario).
## Adverse Effects
- **Frequent:** Somnolence, fatigue, headache, ataxia, drooling (pediatrics), irritability, constipation, weight gain/loss.
- **Serious:** Opioid-combined respiratory depression, paradoxical agitation/hyperactivity, dependence/tolerance, withdrawal syndrome (insomnia, tremors, rebound seizures, psychosis), antidepressant-class suicidal ideation.
- **Pediatric-specific:** Potential growth attenuation with chronic therapy; monitor linear growth and BMI.
## Key Drug Interactions
- **Opioids/Additive CNS Depressants (Z-drugs, pregabalin, gabapentin, TCAs, antihistamines, alcohol):** Synergistic sedation and respiratory drive suppression. Co-prescribing requires documented medical justification, lowest effective doses, and explicit patient counseling.
- **CYP3A4 Modulators:** See Dose Adjustments. Inhibition increases active metabolite exposure; induction decreases it.
- **Valproate:** May increase free fractions of concomitant drugs; monitor protein binding and clinical effect.
- **Amitriptyline/Nortriptyline:** Clobazam can inhibit TCA metabolism, raising TCA serum concentrations to toxic ranges.
## Monitoring
- **Baseline & Follow-up:** Sedation scale, gait/balance (fall risk), respiratory status, mood/behavior changes, seizure diaries.
- **Laboratory:** LFTs at initiation and if signs of hepatotoxicity emerge. CBC/metabolic panel per routine AED polytherapy.
- **Growth & Development:** Monthly weight/height tracking in children on therapy >3 months.
- **Dependence Assessment:** Screen for tolerance or craving after ≥4 weeks of continuous use. Plan gradual taper (reduce 10–25% every 1–2 weeks; slower if long-term/high-dose).
## Clinical Pearls
- Active metabolite accumulation drives delayed peak effect and prolongs washout; do not rapid-titrate expecting immediate clinical change.
- Abrupt cessation carries high rebound seizure risk; always implement a structured taper.
- Counsel families to report paradoxical behavioral activation early, as dose reduction or agent switch may be needed.
- Formulary and protocol variations exist across health systems; confirm local ceiling doses and titration windows prior to dispensing.
*Educational Disclaimer: This summary provides general pharmacotherapeutic guidance and does not replace individualized clinical decision-making or current FDA-approved prescribing information. Dosing, safety thresholds, and regulatory status may differ by jurisdiction and patient comorbidity profile. Verify all details against the latest official label, institutional protocols, and real-time clinical resources before implementation.*
